Benchmark Reiterates Buy Rating on Emergent BioSolutions (EBS)
Tweet Send to a Friend
Benchmark analyst Robert Wasserman reiterated a Buy rating and $12.00 price target on Emergent BioSolutions (NYSE: EBS).The analyst commented, "Emergent ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


